Research progress in relationship between lipoprotein(a)and occurrence and development of calcific aortic valve stenosis and related treatment of hyperlipoprotein Aemia
10.13481/j.1671-587X.20240632
- VernacularTitle:脂蛋白a与钙化性主动脉瓣狭窄发生发展的关系及高脂蛋白a血症相关治疗的研究进展
- Author:
Li ZHANG
1
;
Mengyuan ZHANG
;
Binfeng XIA
;
Min KONG
;
Ru WANG
;
Huihui HUANG
;
Xia YIN
Author Information
1. 吉林大学第一医院心血管内科,吉林 长春 130021
- Keywords:
Lipoprotein(a);
Calcific aortic valve stenosis;
Aortic valve calcification;
Hyperlipoprotein Aemia
- From:
Journal of Jilin University(Medicine Edition)
2024;50(6):1763-1772
- CountryChina
- Language:Chinese
-
Abstract:
Lipoprotein(a)[Lp(a)]is a highly polymorphic lipoprotein molecule composed of apolipoprotein A(apo A),apo B100,and cholesterol ester core;calcific aortic valve stenosis(CAVS)is a multifactorial valvular heart disease influenced by both environmental and genetic factors.Lp(a)is an independent risk factor for CAVS and can increase the onset risk of CAVS.Lp(a)plays an important role in the treatment of CAVS.Although surgery is currently the main clinical treatment for CAVS,with further exploration into its pathological mechanism,drug therapy targeting Lp(a)has emerged as a new method.This paper reviews studies about the structure and characteristics of Lp(a),its role in the occurrence and development of CAVS,treatment options related to hyperlipoprotein Aemia,and the studies preventing and treating CAVS by combating inflammation,and enhances the clinicians'understanding and awareness of hyperlipoprotein Aemia and provides new insights for the prevention and targeted drug therapy of CAVS.
